Clinical Trial Update: Combination of Everolimus and 177Lu-DOTATATE in the Treatment of Grades 2 and 3 Refractory Meningioma: a Phase IIb Clinical Trial [Phase 2]

View source ↗

Summary

A Phase IIb trial is evaluating the combination of Everolimus and Lutetium-177 dotatate for grades 2 and 3 refractory meningioma, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningioma

Drugs mentioned

• Everolimus (everolimus)
• Lutetium-177 DOTATATE (Lutathera) (lutetium-177 dotatate)

Snippet

Sponsor: Central Hospital, Nancy, France | Conditions: Meningioma | Phase 2 | Status: RECRUITING